Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from IDEAYA Biosciences

IDEAYA Biosciences Spotlights Darovasertib Win, FDA Review Path at Oncology Summit

IDEAYA Biosciences (NASDAQ:IDYA) executives highlighted recent clinical progress across the company’s oncology pipeline during a fireside chat at TD Cowen’s seventh annual Oncology Innovation Summit, with the discussion focused primarily on darovasertib combinations in uveal melanoma and several ear

IDEAYA Biosciences Eyes Busy 2026 as Darovasertib Advances Toward FDA Filing

IDEAYA Biosciences (NASDAQ:IDYA) Chief Executive Yujiro Hata said the precision oncology company is preparing for a busy 2026, led by regulatory and clinical milestones for darovasertib in metastatic uveal melanoma and multiple data readouts across its pipeline. Speaking at a Stifel-hosted event, H

IDEAYA Biosciences Says Melanoma Drug on Track for NDA After Strong Trial Data

IDEAYA Biosciences (NASDAQ:IDYA) said its lead oncology program remains on track for a regulatory submission after reporting positive top-line data in first-line metastatic melanoma, while also highlighting several pipeline programs during a presentation at the Bank of America Global Healthcare Conf

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

12 Health Care Stocks Moving In Wednesday's After-Market Session

Gainers Enochian BioSciences (NASDAQ:ENOB) shares moved upwards by 27.8% to $2.3 during Wednesday's after-market session. The market value of their outstanding shares is at $121.7 million.

12 Health Care Stocks Moving In Monday's Intraday Session

12 Health Care Stocks Moving In Monday's Intraday Session

Recap of Wednesday's Biotech Catalysts - End of The Day Summary

IDEAYA Biosciences (NASDAQ:IDYA) has entered into a clinical trial collaboration and supply agreement with Amgen Inc. to evaluate the efficacy and safety of IDE397 with Amgen's AMG 193 in a Phase 1 clinical trial. IDEAYA shares traded in a range of $14.59 to $15.82 on a day volume of 130.58…

inkl

Read news from The Economist, FT, and more,
with one subscription

Ideaya Nominates Potential First-In-Class Pol Theta Helicase Inhibitor In Collaboration With GSK

Ideaya Nominates Potential First-In-Class Pol Theta Helicase Inhibitor In Collaboration With GSK

Ideaya Biosciences Inc (NASDAQ:IDYA) has selected a potential first-in-class Pol Theta Helicase development candidate, a small molecule inhibitor of the helicase domain of DNA Polymerase Theta. Ideaya is collaborating with GSK plc (NYSE:GSK) on IND-enabling studies to support the evaluation of the Pol Theta Helicase candidate in combination with niraparib, GSK's PARP inhibitor, in tumors with…

Recap: IDEAYA Biosciences Q1 Earnings

Recap: IDEAYA Biosciences Q1 Earnings

IDEAYA Biosciences (NASDAQ:IDYA) reported its Q1 earnings results on Tuesday, May 10, 2022 at 06:00 AM. Here's what investors need to know about the announcement.

FDA Grants Orphan Drug Designation For IDEAYA's Darovasertib For Uveal Melanoma

FDA Grants Orphan Drug Designation For IDEAYA's Darovasertib For Uveal Melanoma

The U.S. Food and Drug Administration (FDA) has granted orphan-drug designation to IDEAYA Biosciences (NASDAQ: IDYA) for its drug candidate Darovasertib for the treatment of uveal melanoma.

Recap: IDEAYA Biosciences Q4 Earnings

Recap: IDEAYA Biosciences Q4 Earnings

IDEAYA Biosciences (NASDAQ:IDYA) reported its Q4 earnings results on Tuesday, March 15, 2022 at 06:00 AM. Here's what investors need to know about the announcement.

Earnings Scheduled For March 15, 2022

Earnings Scheduled For March 15, 2022

Companies Reporting Before The Bell • IDEAYA Biosciences (NASDAQ:IDYA) is likely to report quarterly loss at $0.31 per share on revenue of $8.98 million.

IDEAYA Biosciences's Earnings: A Preview

IDEAYA Biosciences's Earnings: A Preview

IDEAYA Biosciences (NASDAQ:IDYA) is set to give its latest quarterly earnings report on Tuesday, 2022-03-15. Here's what investors need to know before the announcement. Analysts estimate that IDEAYA Biosciences will report an earnings per share (EPS) of $-0.31.

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Food and Drug Administration

European Medicines Agency

US Food and Drug Administration

Rhythm Pharmaceuticals

IDEAYA Biosciences

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

389,013 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play